Key Takeaways:
- Pfizer and BioNTech are contesting a UK court ruling favoring Moderna's vaccine patent.
- Analysts predict a potential 12.15% upside for Pfizer stock with a cautious "Hold" recommendation.
- GuruFocus estimates Pfizer's fair value at $27.27, reflecting a 6.69% potential increase.
Pfizer (PFE, Financial) and BioNTech are engaged in a complex legal dispute, contesting a UK court decision that recently upheld Moderna's (MRNA) COVID-19 vaccine patent. This case is just one facet of a broader international debate over vaccine intellectual property rights, with similar cases previously addressed in both Germany and the United States.
Wall Street Analysts Forecast
According to projections made by 21 financial analysts, Pfizer Inc (PFE, Financial) has an average one-year price target of $28.67, showing a wide range with a high of $41.49 and a low of $23.00. This average target suggests a potential upside of 12.15% from the current stock price of $25.56. For more detailed estimates, please refer to the Pfizer Inc (PFE) Forecast page.
In terms of analyst ratings, 25 brokerage firms have collectively rated Pfizer Inc (PFE, Financial) at an average of 2.6 on a scale from 1 to 5. A rating of 1 indicates a "Strong Buy," while 5 signifies a "Sell." This places Pfizer in the "Hold" category, warranting a cautious approach for investors.
Understanding Pfizer's GF Value
GuruFocus projects that the estimated GF Value of Pfizer Inc (PFE, Financial) in one year's time is $27.27. This estimate suggests a modest upside potential of 6.69% from the current trading price of $25.56. The GF Value represents GuruFocus' assessment of fair market value, calculated by analyzing historical trading multiples, past growth performance, and anticipated future business outcomes. For a comprehensive review, visit the Pfizer Inc (PFE) Summary page.
In conclusion, while Pfizer faces ongoing legal challenges, its stock offers a potential upside as per current analyst and GuruFocus projections. Investors should weigh these forecasts alongside external factors influencing the pharmaceutical sector.
